Dopamine

Urinary dopamine can contribute to investigations for neuroblastoma and selected other tumors that produce catecholamines. Its established clinical role is within appropriately validated testing interpreted alongside other markers, symptoms, and imaging. Evidence does not establish a benefit from ordering it as a routine wellness baseline or using it to assess your brain's dopamine supply.

Where Urine Dopamine Comes From

Dopamine belongs to the catecholamine family of chemical messengers, which also includes adrenaline and noradrenaline. Your body makes it from the amino acid tyrosine, first producing L-DOPA and then converting that into dopamine. Some dopamine becomes noradrenaline; some is broken down into other molecules, including homovanillic acid, usually shortened to HVA.

Much of the free dopamine in urine comes from the kidneys converting circulating L-DOPA into dopamine. Human studies support this local production as the main source under ordinary conditions. Within the kidneys, dopamine helps regulate how much sodium returns to the blood and how much leaves in urine. This supply is largely separate from the dopamine involved in movement and reward in the brain.

What This Measurement Includes

This test measures dopamine in urine using liquid chromatography with mass spectrometry, or LC-MS. The method separates compounds and identifies them through characteristic molecular signals. The catalog reports results in mcg/g, but does not specify whether the assay measures free or total dopamine, whether collection is random or timed, or what the gram denominator represents. These details need confirmation from the performing laboratory before published findings can be applied to your result.

Free dopamine is dopamine that isn't chemically attached to another molecule. Total dopamine measurements also include dopamine released from those attachments during sample processing. Both can be measured by mass spectrometry, so LC-MS alone doesn't identify the fraction. Much of the research discussed here concerns free urinary dopamine.

Many urine assays report dopamine relative to creatinine to reduce the effect of urine dilution. Creatinine is a waste product linked to muscle metabolism. If your report confirms this correction, the ratio still depends partly on creatinine production and excretion. It isn't interchangeable with the total amount excreted over a day.

Childhood Neuroblastoma

Neuroblastoma develops from immature nerve cells and mainly affects young children. Many tumors produce catecholamines and their breakdown products. Urinary HVA and vanillylmandelic acid, usually shortened to VMA, are commonly used in its diagnostic workup. VMA comes from the breakdown of noradrenaline and adrenaline. Some centers use broader panels that include dopamine.

The improvement in detection belonged to the entire eight-marker panel. It cannot be attributed to adding dopamine alone, and the study did not validate this specific catalog assay. A positive panel also required follow-up because false-positive results were more frequent.

Follow-up research remains promising. A 2025 retrospective study of 153 children with high-risk neuroblastoma found that a positive eight-marker urine panel during otherwise complete remission was associated with subsequent relapse and poorer survival. The study used both mass spectrometry and another chromatographic detection method. Urinary catecholamines are not part of the formal response criteria used in that study, which relied on imaging and bone marrow assessment. The findings support studying them as additional information.

Adrenal and Paraganglion Tumors in Adults

Pheochromocytomas arise in the adrenal glands, while paragangliomas arise in related cells elsewhere in the body. Many produce noradrenaline or adrenaline. Predominantly dopamine-producing tumors are rare and may lack the blood pressure surges associated with other catecholamine-producing tumors.

The established initial biochemical tests are plasma free metanephrines or urinary fractionated metanephrines. These measure breakdown products of adrenaline and noradrenaline. Plasma 3-methoxytyramine measures a dopamine breakdown product and can add information in selected cases, including some head and neck paragangliomas. Urinary dopamine has a supporting role and cannot reliably exclude these tumors.

In a prospective study of 2,056 people evaluated for these tumors, plasma testing performed better than the urine panels among people at higher risk. Performance was similar among those at lower risk. The study compared metanephrines and methoxytyramine, so it was not a direct comparison of this urine dopamine assay with a blood test.

A separate exploratory study followed 27 people with advanced pheochromocytoma or paraganglioma receiving radioactive MIBG treatment. Those with at least one tumor deposit that failed to take up the treatment had roughly twice the median daily urinary dopamine of those without such deposits. The analysis was small and unadjusted. It measured 24-hour excretion, so its numerical results cannot be applied directly to this mcg/g measurement or used alone to choose treatment.

Kidney Function and Blood Pressure

Studies of chronic kidney disease have found lower free urinary dopamine with poorer kidney function. In one study of 40 kidney transplant recipients, the group with the weakest filtration had about 43% lower median free urinary dopamine than the group with the best-preserved filtration. This was a cross-sectional comparison using mass-spectrometry profiling, not a validation of this particular assay or evidence that a falling result predicts future kidney damage.

Research on kidney scarring associated with hypertension also found changes in urinary dopamine and the activity of genes involved in its production. The reported 30% to 70% reductions concerned urinary excretion of several different compounds. They were not a direct measurement of how much kidney dopamine production had fallen.

These findings help explain why kidney function affects interpretation. They do not establish urinary dopamine as a diagnostic or monitoring test for kidney disease. An isolated low result cannot identify kidney damage, and there is no demonstrated benefit from trying to raise it to protect your kidneys or lower your blood pressure.

Brain, Mood, and Stress

Urinary dopamine reflects production and handling outside the brain. Dopamine crosses the blood-brain barrier poorly, and the kidneys contribute heavily to the free dopamine in urine. This measurement has no established role in diagnosing a brain dopamine deficiency, ADHD, depression, or Parkinson's disease.

Exploratory findings do exist. In a study of 100 workers, higher self-reported stress was associated with lower morning urinary dopamine and HVA. The analysis used concentrations per volume, which differ from a result reported in mcg/g. A group association does not establish a diagnostic test or show that changing the urine result improves stress.

One ADHD study found differences in urinary dopamine 4-sulfate and isohomovanillic acid. These are different molecules from dopamine, so their findings cannot be transferred to this assay.

DOPA decarboxylase is a protein that helps make dopamine. Parkinson's research has found higher amounts of this protein in urine and spinal fluid in some affected people and people carrying certain risk variants. Measuring that protein is different from measuring dopamine, even when both analyses use mass spectrometry.

When Results Can Be Misleading

• Medication effects: levodopa is converted into dopamine and can markedly increase urinary dopamine without a tumor. This is a real biological increase, so using LC-MS does not remove it. Other medicines can affect catecholamine production or breakdown, but the direction and size of their effects depend on the drug and assay.
• Food and the measured fraction: a controlled mass-spectrometry study found that catecholamine-rich foods increased free urinary dopamine modestly and total dopamine much more. A later small LC-MS/MS study found generally limited effects on free dopamine. These results do not establish that diet is irrelevant, or that total dopamine is only an issue with older methods.
• Kidney function and creatinine correction: impaired kidney function can reduce free dopamine excretion. If the result is corrected for creatinine, differences in muscle mass, diet, and creatinine excretion can also affect the ratio.
• Exercise and collection timing: an older study using a different analytical method found that exercise temporarily lowered urinary dopamine despite raising plasma dopamine. That does not establish a predictable response for this LC-MS assay or a universal period for avoiding exercise.
• Sample handling: dopamine can break down during unsuitable storage. Preservation, temperature, and transport requirements depend on the laboratory's validated procedure.
• LC-MS limitations: other substances in urine can suppress or strengthen the instrument's signal, and compounds that are not adequately separated can interfere. Laboratory validation and quality controls reduce these problems, but mass spectrometry does not make every result error-free.

Age and sex also affect interpretation. In a study of 956 adults using an older chromatographic method, daily dopamine excretion declined with age and was slightly higher in men. After correction for creatinine, values were slightly higher in women, and the age association remained in women but not men. Daily totals and creatinine-corrected results therefore describe different patterns.

Interpreting Changes Over Time

Repeat measurements can help follow a known dopamine-producing tumor when the marker was informative at diagnosis and the same validated collection and laboratory methods are used. Interpretation still depends on other markers and the rest of the disease assessment. A stable result does not exclude cancer, and a falling result in an otherwise healthy person has no validated meaning as a measure of aging or declining kidney health.